JP7029172B2 - 骨量減少と関連する疾病を治療又は予防し、骨格構造及び生体力学的骨強度を改善する組成物 - Google Patents

骨量減少と関連する疾病を治療又は予防し、骨格構造及び生体力学的骨強度を改善する組成物 Download PDF

Info

Publication number
JP7029172B2
JP7029172B2 JP2018228252A JP2018228252A JP7029172B2 JP 7029172 B2 JP7029172 B2 JP 7029172B2 JP 2018228252 A JP2018228252 A JP 2018228252A JP 2018228252 A JP2018228252 A JP 2018228252A JP 7029172 B2 JP7029172 B2 JP 7029172B2
Authority
JP
Japan
Prior art keywords
composition
bone
day
genistein
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018228252A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019099579A (ja
JP2019099579A5 (https=
Inventor
王上達
許宸
蘇南維
Original Assignee
休斯生物科技股▲ふん▼有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 休斯生物科技股▲ふん▼有限公司 filed Critical 休斯生物科技股▲ふん▼有限公司
Publication of JP2019099579A publication Critical patent/JP2019099579A/ja
Publication of JP2019099579A5 publication Critical patent/JP2019099579A5/ja
Application granted granted Critical
Publication of JP7029172B2 publication Critical patent/JP7029172B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
JP2018228252A 2017-12-07 2018-12-05 骨量減少と関連する疾病を治療又は予防し、骨格構造及び生体力学的骨強度を改善する組成物 Active JP7029172B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762595697P 2017-12-07 2017-12-07
US62/595,697 2017-12-07

Publications (3)

Publication Number Publication Date
JP2019099579A JP2019099579A (ja) 2019-06-24
JP2019099579A5 JP2019099579A5 (https=) 2021-08-12
JP7029172B2 true JP7029172B2 (ja) 2022-03-03

Family

ID=64559585

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018228252A Active JP7029172B2 (ja) 2017-12-07 2018-12-05 骨量減少と関連する疾病を治療又は予防し、骨格構造及び生体力学的骨強度を改善する組成物

Country Status (6)

Country Link
US (1) US10881634B2 (https=)
EP (1) EP3494973B1 (https=)
JP (1) JP7029172B2 (https=)
KR (1) KR102376603B1 (https=)
CN (1) CN109939118A (https=)
TW (1) TWI756495B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025117337A1 (en) * 2023-11-28 2025-06-05 GreenStone Biosciences, Inc. Genistein phosphate derivatives
CN118359663B (zh) * 2024-04-26 2024-12-13 西安交通大学医学院第一附属医院 线粒体靶向染料木素衍生物及其在制备抗心肌缺血再灌注损伤药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999063995A1 (en) 1998-06-12 1999-12-16 Vyrex Corporation Isoflavone derivatives
US20020111466A1 (en) 2000-12-15 2002-08-15 Hendler Sheldon S. Isoflavone derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007511542A (ja) * 2003-11-18 2007-05-10 ノボゲン リサーチ ピーティーワイ リミテッド イソフラボノイドプロドラッグ、その組成物、それらを使用する治療法
EP2182957A4 (en) * 2007-07-31 2012-07-18 Limerick Biopharma Inc PHOSPHORYLATED PYRONANALOGES AND CORRESPONDING METHODS
TR201004464A2 (tr) * 2010-06-03 2012-11-21 B�Lg�� Mahmut Kemik erimesi için formülasyon.
US8900635B2 (en) * 2010-11-15 2014-12-02 Humanetics Corporation Nanoparticle isoflavone compositions and methods of making and using the same
CN102351828A (zh) * 2011-08-16 2012-02-15 李荣立 一种提取金雀异黄素的新工艺
CN102488210B (zh) * 2011-12-27 2013-06-19 西南大学 染料木素水凝胶的复合物及其制备方法
CN105381470B (zh) * 2015-11-27 2018-11-02 广东医科大学 一种改性染料木素及其应用
TWI670374B (zh) * 2016-04-25 2019-09-01 國立臺灣大學 具有苯並吡喃酮類磷酸酯合成酶活性之多肽、包含編碼該多肽之核酸序列之微生物及苯並吡喃酮類磷酸酯衍生物之製備方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999063995A1 (en) 1998-06-12 1999-12-16 Vyrex Corporation Isoflavone derivatives
US20020111466A1 (en) 2000-12-15 2002-08-15 Hendler Sheldon S. Isoflavone derivatives

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
「新医薬品の臨床評価に関する一般指針について」（薬新薬第四三号）各都道府県衛生主管部局長あて厚生省薬務局新医薬品課長通知，1992年，第１－１２頁
Guidance for Industry, Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers，U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)，2005年，pp. 1-27
J Bone Miner Metab，2002年，Vol. 20，pp. 148-155
JOURNAL OF FUNCTIONAL FOODS，2015年，Vol. 13，pp. 323-335
Trace Nutrients Research，2010年，Vol. 27，pp. 35-38
日本内科学会雑誌，2005年，Vol. 94, No. 4，pp. 670-674 (pp. (64)-(68))
日本比較内分泌学会ニュース，2001年，Vol. 2001, No. 101，pp. 18-20
臨床薬理，2000年，Vol. 31, No. 3，pp. 539-540
順天堂医学，2004年，Vol. 49, No. 4，pp. 440-444

Also Published As

Publication number Publication date
EP3494973A1 (en) 2019-06-12
JP2019099579A (ja) 2019-06-24
TW201924691A (zh) 2019-07-01
EP3494973B1 (en) 2021-07-28
CN109939118A (zh) 2019-06-28
US10881634B2 (en) 2021-01-05
KR102376603B1 (ko) 2022-03-18
US20190175545A1 (en) 2019-06-13
KR20190067695A (ko) 2019-06-17
TWI756495B (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
EP2730286B1 (en) Composition for maintaining bone health and for treating osteoarthritis and osteoarthrosis of the joints
D'Anna et al. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo-controlled study
CN101791341B (zh) 一种中药组合物在制备治疗骨质疏松症药物中的应用
JP2012511547A (ja) イソフラボン組成物
Liu et al. Coadministration of puerarin (low dose) and zinc attenuates bone loss and suppresses bone marrow adiposity in ovariectomized rats
JP7029172B2 (ja) 骨量減少と関連する疾病を治療又は予防し、骨格構造及び生体力学的骨強度を改善する組成物
Devareddy et al. The effects of fructo-oligosaccharides in combination with soy protein on bone in osteopenic ovariectomized rats
US11116781B2 (en) Composition, containing Loganin or a derivative thereof as an active ingredient for preventing, remedying, or treating female climacteric syndrome
Lee et al. Evaluation of effectiveness and safety of natural plants extract (Estromon®) on perimenopausal women for 1 year
CN102028751B (zh) 用作植物雌激素的中药组合物及其用途
Sheng et al. Phytochemical molecule icariin stimulates osteogenic but inhibits adipogenic differentiation of mesenchymal stem cells
US7914821B2 (en) Pharmaceutical composition for prevention and/or treatment of bone loss
Koyama Extracts of marine algae show inhibitory activity against osteoclast differentiation
RU2585108C1 (ru) Композиция для восстановления хрящевой и костной ткани при остеопорозе
CN119733034B (zh) 一种促进骨折再生与愈合的复方制剂及其制备方法
CN115702903A (zh) 水晶兰苷在促进骨折愈合中的应用
Batool et al. Journal of Agriculture and Food Research
RU2601112C1 (ru) Способ восстановления хрящевой и костной ткани при остеопорозе
JP5627081B2 (ja) 骨粗鬆症予防・治療剤及び健康食品
CN101273985A (zh) 一种改善女性更年期综合症胶囊的组配方法及制作工艺
Abdelrahman et al. A COMPARATIVE STUDY OF THE EFFECT OF GREEN VERSUS ROASTED COFFEE ON THE GROWTH OF MANDIBULAR CONDYLE IN ALBINO RATS OFFSPRING
US20200129573A1 (en) Use of euycoma longifolia extract in alleviating symptoms and/or conditions associated with hormonal imbalance in females
TWI474826B (zh) 治療及／或預防骨質疏鬆症之組合物
KR20140064262A (ko) 골다공증 예방 및 치료용 활성화 이온 칼슘 조성물
CN111357979A (zh) 抑制高脂引起的肥胖及骨丢失的保健食品组合物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210630

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220210

R150 Certificate of patent or registration of utility model

Ref document number: 7029172

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250